Humacyte

Humacyte

Yahoo Finance • 18 days ago

Biggest stock movers: ORCL, HUMA, and more

[Abstract Finance Technology Concept] koto_feja Stock futures rose Thursday morning as markets staged a tentative recovery from Wednesday's steep AI-led sell-off. Market sentiment was further supported as crude oil prices edged lower, rev... Full story

Yahoo Finance • 18 days ago

Humacyte's ATEV Meets Primary Goal In Phase3 V012 Trial For Dialysis Access; Prices $50 Mln Offering

(RTTNews) - Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform, announced positive top-line interim results from the Phase 3 study dubbed V012 by meeting the trial's primary endpoint of the acellular tissue-engineered vessel... Full story

Yahoo Finance • 18 days ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pri... Full story

Yahoo Finance • 18 days ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it... Full story

Yahoo Finance • last month

Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization

We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Humacyte, Inc. (NASDAQ:HUMA) is among the best penny stocks under $1 according to hedge funds. TheFly reported on May 14 that HUMA saw its price ta... Full story

Yahoo Finance • 2 months ago

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Huma... Full story

Yahoo Finance • 3 months ago

Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity

Humacyte, Inc. (NASDAQ:HUMA) is one of the penny stocks with potential to rise 1000 percent. On March 27, 2026, BTIG maintained its Buy rating on Humacyte but cut its price target to $3 from $6 after the company reported fourth-quarter an... Full story

Yahoo Finance • 3 months ago

Pre-Market Earnings Report for March 27, 2026 : CCL, TMC, CUK, KOPN, SBC, AUTL, SNWV, HUMA, SLE

The following companies are expected to report earnings prior to market open on 03/27/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Carnival Corporation (CCL)is reporting for the quarter ending Februa... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index down 0.4% and the St PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 months ago

Sector Update: Health Care Stocks Decline Monday Afternoon

Health care stocks were lower Monday afternoon, with the NYSE Health Care Index shedding 0.9% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 months ago

Humacyte jumps as U.S. legislation backs bioengineered vessels

[Capitol Building Sunset - Washington DC] Douglas Rissing Humacyte (HUMA [https://seekingalpha.com/symbol/HUMA]) added ~27% on Monday after the Durham, North Carolina-based biotech said that the U.S. Congress has passed legislation provid... Full story

Yahoo Finance • 5 months ago

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that th... Full story

Yahoo Finance • 6 months ago

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - -... Full story

Yahoo Finance • 6 months ago

Humacyte announces credit facility of $77.5M with Avenue Capital

* Humacyte (HUMA [https://seekingalpha.com/symbol/HUMA]) said on Tuesday that it has entered into a credit facility [https://seekingalpha.com/pr/20340828-humacyte-announces-credit-facility-of-up-to-77_5-million-with-avenue-capital] with... Full story

Yahoo Finance • 8 months ago

Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise

Earnings Call Insights: Humacyte, Inc. (HUMA) Q3 2025 MANAGEMENT VIEW * Laura Niklason, Founder, President, CEO & Director, highlighted significant progress in the commercial launch of Symvess, reporting "product sales improved to $703... Full story

Yahoo Finance • 8 months ago

Strong Earnings and Biotech Resilience Define the Midweek Momentum

DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB: KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe... Full story

Yahoo Finance • 8 months ago

Humacyte, Inc. Q3 Loss Narrows

(RTTNews) - Humacyte, Inc. (HUMA) announced Loss for third quarter of -$17.51 million The company's bottom line totaled -$17.51 million, or -$0.11 per share. This compares with -$39.20 million, or -$0.33 per share, last year. Humacyte,... Full story

Yahoo Finance • 8 months ago

Humacyte GAAP EPS of -$0.11 beats by $0.05, revenue of $0.75M misses by $0.17M

* Humacyte press release [https://seekingalpha.com/pr/20303336-humacyte-announces-third-quarter-2025-financial-results-and-provides-business-update] (HUMA [https://seekingalpha.com/symbol/HUMA]): Q3 GAAP EPS of -$0.11 beats by $0.05. *... Full story

Yahoo Finance • 8 months ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial... Full story

Yahoo Finance • 9 months ago

Humacyte rises after positive data from humanitarian study of Symvess

[Doctor working in lab during COVID-19 outbreak] Morsa Images/DigitalVision via Getty Images Humacyte (NASDAQ:HUMA [https://seekingalpha.com/symbol/HUMA]) shares surged following the release of data from a humanitarian initiative that uti... Full story